4 | Regional hospital September 2011 | AA | Regional hospital CT July 20, 2011 | Frontotemporal mass (4 × 3.7 cm) | Regional hospital September 15, 2011 Total tumor resection | Regional radiology MRI August 29, 2012 | Recurrence |
|
|
|
| Regional hospital October 26, 2012 | GBM |
|
| Regional hospital October 25, 2012 Total tumor resection | Regional radiology MRI February 21, 2013 Mass 3.8 × 3.6 cm | Recurrence |
|
|
|
|
|
|
|
| BC. February 21, 2013 PB, erlotinib, everolimus, BVZ, pazopanib, TMZ |
|
|
|
|
|
|
|
|
|
| Discontinued erlotinib after 6 weeks and replaced by dasatinib. Discontinued dasatinib after 9 months, and everolimus, BVZ and TMZ after 1 year. Discontinued pazopanib in August 2013 and PB in April 2014. |
|
| Regional radiology MRI April 8, 2013 | CR | IDH1-R132C mutation, TP53 loss-P190 del, Splice site 672 + 2 T7G, ATRX loss-F395fs19, FBXW7-K189fs66 (tissue) |
5 | Regional hospital May 20, 2013 | GBM | Regional hospital MRI May 2, 2013 | Enhancing lesion in corpus callosum and corona radiata | None | Regional radiology MRI May 2, 2013 | Left frontal mass (Baseline) |
|
|
|
|
|
|
|
| BC. May 29, 2013 PB, pazopanib, everolimus, lapatinib, BVZ |
|
| Regional radiology MRI July 11, 2013 | PR | PIK3R1-L380-del, CDKN2A and CDKN2B-Loss, HF1-E318fs*58 mutation (tissue) |
6 | Regional hospital August 5, 2013 | GBM | Regional radiology MRI July 24, 2013 | Left temporal-parietal-occipital region tumor | Tumor resection August 5, 2013 |
|
|
|
|
|
|
|
|
|
| RT and TMZ August 28, 2013-September 30, 2013 |
|
|
|
|
|
|
|
|
|
| TMZ 290 mg for 5 days of a 28 day cycle ×6 | Regional radiology MRI October 12, 2013 | Enhancing lesion 1.2 × 0.9 cm |
|
|
|
|
|
|
|
| BC. November 1, 2013 PB, pazopanib, everolimus, dasatinib, erlotinib |
|
| Regional radiology MRIs February 19, 2014 | SD (post-operative changes) | PTEN-A79T mutation, EGFR-A289D subclonal amplification, EGFRVIII mutation, G598V mutation (subclonal), L62R mutation, CDKN2A/B/C loss (tissue) |
7 | Regional hospital September 6, 2013 | GBM | Regional radiology MRI September 2, 2013 | Enhancing left parietal temporal tumor | RT and TMZ September 2013-November 26, 2013 |
|
|
|
|
|
|
|
|
|
| TMZ-December 4, 2013 | Regional radiology MRI January 22, 2014 | Large enhancing tumor in the left cerebral hemisphere |
|
|
|
|
|
|
|
| BC. January 22, 2014 PB, pazopanib, everolimus, dasatinib, BVZ |
|
| Regional radiology CT/PET April 24, 2014 | PD | PTEN-R130e mutation, CDKN2A/B-loss, VHL-N67M mutation (tissue) |
8 | Regional medical center January 27, 2014 | GBM | Regional hospital MRI January 25, 2014 | Butterfly shaped glioma surrounding the corpus callosum | RT, 30 treatments with TMZ 160 mg daily February 24, 2014- April 4, 2014 |
|
|
|
|
|
|
|
|
|
| TMZ 320 mg, 5 days on and 23 days off May 12, 2014-June 4, 2014 |
|
|
|
|
|
|
|
|
|
| BC. June 6, 2014 PB, dasatinib, everolimus, pazopanib, BVZ. Discontinued everolimus July 10, 2014. Discontinued treatment July 31, 2014. BVZ August 25, 2014-September 8, 2014 (2×). PB August 25- September 8, 2014. Erlotinib September 10-September 15, 2014 |
|
| Regional hospital MRI September 3, 2014 | SD | VEGF-elevated (blood) EGFR-amplification CDKN2A/B-loss (tissue) |